Hormonal Causes of Gynecomastia — When to Investigate
Most adult gynecomastia does not require hormonal blood tests. Workup is indicated specifically when: onset is recent (under 6 months), enlargement is rapid or painful, presentation is unilateral, a hard fixed mass is palpable, or pubertal gynecomastia persists past age 18–20. The standard panel includes total/free testosterone, LH, FSH, prolactin, oestradiol, β-hCG, liver and thyroid function. Rare but critical conditions to exclude include testicular tumours, adrenal tumours, hCG-secreting carcinomas, pituitary adenomas, and Klinefelter syndrome.
Not every gynecomastia requires a hormonal workup. Longstanding stable gynecomastia in an otherwise healthy adult man rarely reveals an underlying endocrine disorder. But some presentations — recent onset, rapid progression, unilateral disease, tenderness, a palpable distinct mass, or unusual patient profiles — mandate investigation before surgery. Missing an underlying pituitary adenoma, hypogonadism, liver disease, or rare malignancy is a clinical error surgery cannot correct.
Core principle: the decision to investigate is driven by clinical features, not by patient preference or age. A 25-year-old with recent-onset, painful, rapidly progressive unilateral gynecomastia gets a workup. A 35-year-old with longstanding stable bilateral gynecomastia and clear steroid history does not — his cause is already identified. Knowing when to test is as important as knowing what to test.
Physiological causes (no workup required)
- Neonatal gynecomastia — transient, from maternal oestrogens; resolves in weeks
- Pubertal gynecomastia — onset age 10–14, typically resolves within 18 months without intervention. Persistent gynecomastia beyond age 20 warrants investigation
- Senescent gynecomastia — after age 60, physiological testosterone decline and adipose aromatisation drive the condition. Workup only if atypical features present
Pathological causes warranting investigation
Primary hypogonadism
Testicular failure (Klinefelter syndrome, mumps orchitis, trauma, chemotherapy, varicocele) — low testosterone with compensatory elevated LH/FSH. Klinefelter syndrome (47,XXY) is the most important to identify because it carries a significantly elevated breast cancer risk (20-50× the general male population) — affecting long-term surveillance strategy.
Secondary hypogonadism
Pituitary or hypothalamic dysfunction — low testosterone with inappropriately normal or low LH/FSH. Causes include prolactinoma (prolactin-secreting pituitary tumour), non-functioning pituitary adenoma, Kallmann syndrome, or severe systemic illness.
Hyperthyroidism
Increases sex-hormone-binding globulin (SHBG), lowering free testosterone relative to estradiol. Gynecomastia may be the presenting feature. Thyroid function tests (TSH, free T4) are part of the standard workup.
Chronic liver disease
Impaired hepatic clearance of oestrogens and androgen-binding proteins produces an altered testosterone-to-oestrogen ratio. Alcoholism, NAFLD, hepatitis, and cirrhosis all contribute. Spironolactone (often used in cirrhosis for ascites) compounds the issue pharmacologically.
Renal failure / chronic dialysis
Uraemia suppresses testosterone production and alters sex steroid metabolism. Gynecomastia in dialysis patients is common.
Tumours — rare but must not be missed
- Testicular tumours — Leydig cell, Sertoli cell, or germ cell (β-hCG secreting). Warrants testicular examination at consultation; ultrasound if any mass or asymmetry
- Adrenal tumours — estrogen-secreting carcinoma. Rare. Elevated estradiol with suppressed LH/FSH
- Extragonadal germ cell tumours — mediastinal or retroperitoneal, secreting hCG. Elevated hCG points here
- Lung carcinoma — ectopic hCG secretion from paraneoplastic lung cancer. Rare but classically presents with gynecomastia as a paraneoplastic sign
These are uncommon but their detection at the pre-operative workup stage, rather than after years of misdiagnosis, is the entire point of hormonal screening.
Drug-induced gynecomastia
The most common cause of drug-induced gynecomastia in routine clinical populations (excluding anabolic steroids, covered separately):
| Class | Examples | Mechanism |
|---|---|---|
| Anti-androgens | Spironolactone, flutamide, bicalutamide, cyproterone | Androgen receptor blockade |
| 5α-reductase inhibitors | Finasteride, dutasteride (high dose/chronic) | DHT reduction, relative estrogen excess |
| H2 antagonists | Cimetidine | Weak anti-androgen activity |
| Antifungals | Ketoconazole (chronic) | Impaired androgen synthesis |
| Antipsychotics | Haloperidol, risperidone | Hyperprolactinaemia |
| Antihypertensives | Methyldopa, verapamil, amlodipine | Variable |
| Protease inhibitors (HIV) | Efavirenz, indinavir | Oestrogen-like activity |
| Recreational | Cannabis (chronic heavy), heroin, methadone | Variable endocrine disruption |
| Phyto-oestrogens | Soy (extreme intake), lavender / tea-tree oils | Direct oestrogen receptor activity (rare) |
When to order a hormonal panel — indications
- Onset within the last 6 months — active proliferation phase, workup can reveal a reversible cause
- Rapid progression over weeks rather than months
- Significant tenderness or pain — inflammatory / active phase
- Unilateral presentation — raises differential of neoplasm
- Persistent pubertal gynecomastia beyond age 20
- Systemic symptoms — weight loss, fatigue, visual disturbances, headaches, testicular pain or swelling
- Palpable hard or fixed mass distinct from the normal glandular disc — mandates imaging and possibly biopsy before surgery
- Abnormal testicular examination — testis examination is mandatory at gynecomastia consultation
- Family history of breast cancer in male relatives, BRCA, or Klinefelter
The standard hormonal panel
- Total testosterone (morning sample) and free testosterone (if indicated)
- LH and FSH — to localise the hypogonadism (primary vs. secondary)
- Estradiol — measured directly (not calculated)
- Prolactin — elevated in prolactinoma, some drug effects
- β-hCG — elevated in germ cell tumours, hCG-secreting malignancy
- TSH, free T4 — thyroid function
- Liver function tests — ALT, AST, albumin, bilirubin
- Renal function — creatinine, eGFR
- SHBG (selectively) — to calculate bioavailable testosterone
Interpreting abnormal results — referral thresholds
Any significant abnormality — elevated prolactin >upper limit of normal, elevated hCG, low testosterone with inappropriately normal/low LH, or concerning testicular examination — triggers endocrinology referral before surgery is scheduled. Surgery on an undiagnosed pituitary adenoma is poor care. Most hormonal abnormalities can be investigated and managed in a few weeks; scheduling surgery after diagnosis is complete is the norm.
Imaging when indicated
- Breast ultrasound — for unilateral presentation, discrete hard mass, or equivocal examination
- Mammography — rarely needed in typical male gynecomastia but indicated if ultrasound suggests malignancy or patient is elderly with new unilateral disease
- Testicular ultrasound — for abnormal examination, tenderness, or elevated hCG
- Pituitary MRI — for confirmed hyperprolactinaemia or features suggesting pituitary dysfunction
Key references
- Braunstein GD. Gynecomastia. N Engl J Med 2007;357:1229-1237.
- Kanakis GA et al. EAA clinical practice guidelines — gynecomastia evaluation and management. Andrology 2019;7:778-793.
- Johnson RE, Murad MH. Gynecomastia: pathophysiology, evaluation, and management. Mayo Clin Proc 2009;84:1010-1015.
- Narula HS, Carlson HE. Gynaecomastia — pathophysiology, diagnosis and treatment. Nat Rev Endocrinol 2014;10:684-698.
Request a clinical assessment
If your presentation has any of the "red flag" features above, pre-operative workup is part of the consultation pathway. Send your clinical history on WhatsApp for initial assessment.
WhatsApp Dr. ErdalFrequently asked questions
Hormonal workup is not routinely required for longstanding stable gynecomastia in healthy adults. It is specifically indicated when there are red flags: recent onset (under 6 months), rapid progression, unilateral presentation, painful or tender mass, hard or fixed mass distinct from the normal glandular disc, persistent pubertal gynecomastia past age 18–20, or abnormal testicular examination. The standard panel includes testosterone (total and free), LH, FSH, prolactin, oestradiol, β-hCG, and liver/thyroid function.
Common causes include: physiological (puberty, ageing), idiopathic, drug-induced (spironolactone, cimetidine, finasteride at high doses, ketoconazole, anti-androgens, some antipsychotics, methadone), liver disease, kidney failure, hyperthyroidism, malnutrition recovery. Rare but critical: testicular tumours (Leydig, Sertoli, germ cell), adrenal oestrogen-secreting tumours, hCG-secreting lung carcinoma, pituitary adenoma, Klinefelter syndrome (47,XXY).
Rarely, yes. Specific concerning features include: rapid recent enlargement, hard or fixed mass distinct from the normal glandular disc, blood-stained nipple discharge, unilateral mass with palpable lymph nodes, abnormal testicular examination, or unexplained weight loss. These features mandate referral for breast ultrasound, testicular ultrasound, and tumour markers (β-hCG, AFP) before any cosmetic surgery is considered. The vast majority of gynecomastia is benign, but the small minority that is not must be identified before surgery, not after.
It depends on red flags. If you have rapid recent onset (under 6 months), unilateral or painful enlargement, suspicious physical findings, or pubertal gynecomastia persisting past age 18–20, see your primary care physician or an endocrinologist first for hormonal workup. If you have stable longstanding adult gynecomastia without red flags, a direct plastic surgery consultation is reasonable — the surgeon will identify any need for hormonal workup during clinical assessment.